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ABSTRACT 
 
Abdulrahman Allabidi. M.S. Department of Microbiology and Immunology, Wright State  
University, 2013. Comparison Between Flow cytometry And Bead Method In Counting 
CD4 And CD8 T Lymphocytes In Mouse Spleen Cells Suspension. 
 
 
The flow cytometry is gold standard method to count CD4,  CD8 human T  
 
lymphocytes, and calculate CD8 to CD4 ratio  in HIV patients peripheral blood to  
 
stage them and  monitor their  response to  treatment. In this study, a comparison was  
 
made by counting CD4and  CD8 mouse spleen T lymphocytes by flow cytometry, and a  
 
method involving antibody coated latex beads. The bead method yielded results   
 
comparable to those obtained  by  flow cytometry. These results indicate that antibody  
 
coated beads are suitable to determine CD4 and CD8 + T lymphocytes counts in situation  
 
where flow cytometry is not readily available. 
 
  
 
 
 
 
 
iv 
 
 
 
 
HYPOTHESIS 
 
The hypothesis of this study was that the bead method using antibody coated latex beads 
would give results comparable to those of flow cytometry. 
The null hypothesis was that the bead method would not give results comparable to these 
of flow cytometry.  
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Introduction 
The human immunodeficiency virus (HIV) is a member of the genus Lentivirus, 
which is part of the family Retroviridae. Lentiviruses have many shared morphologies 
and biological properties, and  are responsible for  illnesses of  a long incubation period 
(Levy, 1993). Lentiviruses are single-stranded, positive-sense, enveloped RNA viruses. 
Lentiviruses use reverse transcriptase enzyme to replicate their genome. HIV is 
structurally different from other retroviruses in that it is roughly spherical with a diameter 
of about 120 nm which is around 60 times smaller than a red blood cell (McGovern et al., 
2002). HIV contains two copies of positive single-stranded RNA that codes for the virus's 
nine genes.  Enclosing the virus genome a conical shaped capsid which is composed of 
2,000 copies of the viral protein p24 (Kuiken et al., 2008). The single-stranded RNA is 
strongly attached to nucleocapsid proteins, p7, and enzymes needed for the synthesis of 
the virion. These enzymes are reverse transcriptase, proteases, ribonuclease and integrase. 
The virion particle integrity is maintained by a matrix composed of the viral protein p 17 
surrounding the capsid. Two layers of phospholipids form the viral envelop. These two 
layers are taken from the membrane of a human cell when a newly formed virus particle 
buds from the cell. Rooted in the viral envelope proteins from the host cell as well as 70 
copies of a complex HIV protein that emerge through the surface of the virus particle ( 
Kuiken et al., 2008). This Env protein consists of a cap made of three glycoprotein (gp 
120 ) molecules, and a stalk consisting of three gp 41 molecules that anchor the structure 
in to the viral envelope (Chan  et al., 1997). Attachment to and fusion with target cells is  
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the function of  this glycoprotein complex (Chan  et al., 1997).Both  of  these surface 
proteins have been considered as targets of future treatments or vaccines against HIV 
with more concentration on gp 120 (Wyman, 1998). HIV 1 and HIV 2  are the two strains 
of HIV. HIV-1 is the virus that was initially discovered and termed both 
lymphadenopathy-associated virus LAV and human T-lymphotrophic virus- III HTLV-
III. HIV1 is more virulent, and  infectious than HIV 2 (Gilbert  et al.,  2003),  making 
HIV 1 the main cause of the HIV infections around the world. HIV 2 is confined to West 
Africa because of its relatively poor capacity for transmission (Reeves et al., 2002). 
  
Literature Review And Preliminary Data. 
HIV Genome 
The HIV genome consists of seven structural landmarks and nine genes. The 
seven structural landmarks are LTR, TAR, RRE, PE, SLIP, CRS, and INS. The nine 
genes are gag, pol, env, tat, rev, nef, vif, vpr, vpu. In some cases a tenth tev gene a fusion 
of tat env and  rev can be found. The nine or ten genes encode for 19 proteins. Function 
of some HIV gene and proteins are not well known, however the function of some others 
is well known. For example, the structural proteins for new virus particles need the 
genetic information in the genes gag, pol, and env  (Kuiken et al., 2008). The six 
remaining genes, tat, rev, nef, vif, vpr, and vpu (or vpx in the case of HIV-2), regulate the 
proteins that control HIV’s ability to infect cells, produce new copies of virus, or cause 
disease (Kuiken et al.,  2008). HIV uses the Vpr protein (p14) to arrest cell division at 
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G2/M. CD4 (the main HIV receptor), as well as the MHC class I and class II molecules 
are down-regulated by Nef protein (p27) (Garcia et al., 1991; Stumptner-Cuvelette  et al.,  
2001). The release of new virus particles from infected cells is controlled by Vpu protein 
(p16). The RNA sequence known as  the long terminal repeat (LTR)  is located at the 
ends of each  strand of HIV RNA, and contains certain regions that control the  
production of new viruses and can be activated by viral or host cell proteins (Kuiken et 
al., 2008).  
 
Tropism 
CD4+ T cells, macrophages, and microglial cells are the main targets for HIV-1. 
This viral tropism makes HIV target the backbone of human immune system. The virion 
envelope glycoprotein (gp120) attaches to the CD4 molecule and chemokine coreceptors 
on CD 4 cells. This interaction will allow HIV-1 to start the cell entry process. Gp 41, 
another glycoprotein on the viron envelope binds to the chemokine receptors and 
promotes viral and cellular membrane fusion and delivery of viral contents to the host 
cell (Chan et al., 1997).  Non-syncitia-inducing strains of HIV1 (R5 viruses) use the β-
chemokine receptor CCR5 for entry to CD4+ T cells and macrophages. Syncitia-inducing 
strain of HIV1 (X4 viruses)   uses the α-chemokine receptor, CXCR4, for entry in to 
macrophages and CD4+ T cells (Berger et al., 1998). Macrophages are the first cells 
infected by HIV and the source of HIV production when CD4+ cells severely decrease in 
number. Microglial cells act as a reservoir of HIV in the central nervous system. 
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Macrophages fuse into multinucleated giant cells that produce large number of virus in 
tonsils and adenoids of HIV-infected patients (Rappaport, 2014). People with CCR5-Δ32 
mutation are resistant to infection with R5 virus, because this   mutation will prevent the 
R5 viruses from attaching to CCR5 co receptor, decreasing its ability to infect target cells 
(Tanga &  Kaslowa,  2003). Seminal fluid carries both X4 and R5 HIV variants, making 
sexual intercourse one of the main routes of HIV transmission. After infection, the 
virions will target immune cells CD4 and macrophages and disseminate throughout the 
body. By a selection process the R5 virus becomes the predominant strain to be 
transmitted by this pathway (Zhu et al., 1996). R5 HIV is selectively carried by 
spermatozoas as they possess both CCR3 and CCR5 but not CXCR4 on their surface. 
Furthermore, the genital epithelial cells also sequester the X4 virus (Muciaccia  et al., 
2005). At the late stage of HIV infection, there is usually a co-receptor switch In subtype 
B HIV-1 infected patients. This switch will lead to appearance of T-tropic variants that 
can infect a variety of T cells through CXCR4. These variants have a high replication rate  
and are more virulent, causing a tremendous decrease in CD4 cell count , immune system 
failure, and fulminant opportunistic infections (Clevestig et al., 2005). Another way in 
which HIV infection progresses to AIDS  is adaptation of the virus to use CXCR4 instead 
of CCR5 (Moore, 1997).  
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HIV Replication Cycle 
Replication of HIV starts with cell entry and ends with release of virions from the 
infected cells. Adsorption of glycoproteins on HIV surface to receptors on the target cells 
is the starting point of the entry process. The adsorption process starts with the interaction 
of the trimeric envelope complex gp160 spike (gp 120 and gp 41) with   CD4 and a 
chemokine receptor (CCR5 or CXCR4) on the cell surface (figure 1). The next step in the 
entry process is fusion of the viral envelope with the cell membrane and the release of the 
HIV capsid content into the cell. When gp120 is bound to CD4 protein, structural 
changes in the viral envelope complex lead to exposure of  the chemokine binding 
domains of gp120, allowing them to interact with the target chemokine receptor. Gp120 
and CD4 interaction will lead to stabilization of the attachment between the virus and the 
target cell. This reinforcement of the attachment will allows the N-terminal fusion 
peptide of gp41 to penetrate the cell membrane. Collapse of the extracellular portion of 
gp41 into a hairpin occurs when the repeated sequences in gp41, HR1, and HR2 interact. 
This loop structure brings HIV and the target cell close together, allowing fusion of the 
viral envelope with the target cell membrane and entry of the viral capsid (Chan, & Kim 
1998).  
 
Fusion of HIV with the target cell will deliver the HIV RNA and various 
enzymes, including reverse transcriptase, protease, integrase, and ribonuclease, into the 
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target cell (figure 1). The viral single-strand RNA genome will be transcribed into 
double-strand DNA by reverse transcriptase. The transcription occurs during the 
microtubule-facilitated transport to the nucleus. The viral double-strand DNA  
 
 
Figure 1. HIV Replication Cycle And The Site Of Antiretroviral Drug Action. Figure 
adapted from (Engelman, & Cherepanov, 2012). 
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now is ready to be integrated into a target cell chromosome (Chan, & Kim 1998). The 
process of reverse transcription lacks proof reading leading to a high number of 
mutations. These mutations account for the development of drug resistance and help the 
virus to evade the immune system.  
 
The ribonuclease activity of reverse transcriptase allows it to degrade the viral 
RNA during the synthesis of complementary DNA (cDNA). Furthermore, reverse 
transcriptase has a DNA-dependent DNA polymerase activity that produces a sense DNA 
from the antisense cDNA. The sense DNA and its complement form a double-stranded 
viral DNA. The viral double-stranded DNA is then transported into the target cell 
nucleus. The integration of the viral DNA into the target cell's genome is executed by the 
viral integrase enzyme (Zheng et al., 2005). After integration, the integrated viral DNA 
may then lie dormant. The dormant viral DNA is the main cause of the latent HIV 
infection stage. Certain cellular transcription factors especially NF-κB need to be present 
to actively produce the virus. Intracellular levels of NF-κB increase when the T-cells are 
in active status (Zheng et al., 2005). This supports the concept that T- cells that  most 
likely undergoing HIV replication are those currently involved in fighting infection 
(Hiscott et al.,  2001).   
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Viral replication starts when the integrated DNA is transcribed into mRNA. The 
mRNA is then spliced into smaller pieces and exported from the nucleus into the 
cytoplasm. Regulatory proteins Tat (which induces new virus production) and Rev are 
produced by translation of the mRNA in the cytoplasm. Accumulation of   the newly 
formed Rev protein in the nucleus makes Rev protein binds to viral mRNAs and helps 
unspliced RNAs to leave the nucleus (Zheng et al., 2005). The full-length mRNA is the 
coding sequence for the structural proteins Gag and Env. Moreover, the full-length RNA 
is the HIV genome which will binds to the Gag protein to produce   new virus particles 
after packaging. HIV1 is more dominant then HIV2 possibly because of the difference in 
the packaging process. HIV-2 will specifically bind to the mRNA that was used to create 
the Gag protein itself. On the other hand, HIV-1 will bind to any suitable RNA. This 
manner of HIV interaction with RNA indicates that HIV-1 is more mutable than HIV-2 
and for this reason HIV-1 is the most common HIV strain worldwide (Pollard, & Malim 
1998).  
 
In the final stage of the of HIV replication, assembly of new HIV-1 virions starts 
at the plasma membrane of the infected cell. Gp160 will be processed by endoplasmic 
reticulum and Golgi complex. Furin will cleave the gp 160 in to HIV envelope 
glycoproteins gp41 and gp120 at Golgi complex. Gp41 and gp120 will be transported to 
the plasma membrane of the infected cell where gp41 anchors gp120 to the membrane. 
The inner surface of the infected cell plasma membrane is the attachment site for   Gag 
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(p55) and Gag-Pol (p160) along with the HIV genomic RNA. Subsequent to these 
attachments the virion begins to bud from the infected cell. The mature virus will be 
formed after cleavage of the gag polyproteins into capsid, nucleocapsid proteins, and the 
actual matrix. Viral protease is the main mediator of this cleavage process , also the target 
for  antiretroviral drugs of the protease inhibitor class (Figure 1). Only mature viruses are 
able to infect another cell (Hallenberger et al., 2001). High genetic variability is one 
crucial characteristic of HIV. This resulted from its fast replication rate, with approximate 
formation of 1010 virions every day, its high h mutation rate of approximately 3 x 10
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per nucleotide base per cycle of replication , and its  reverse transcriptase  recombination 
ability. This high genetic variability can lead to the production of large number of HIV 
variants in a single infected person during one day. Increase of this variability occurs 
when a single cell is infected by two or more different strains of HIV in the same time 
(Robertson et al., 1995).  
 
Based on the differences in the envelope region, HIV-1 can be characterized into 
three groups M, N, and O. Group M can be subdivided into eight subtypes, and  is the 
most common world wild (Jean K et al., 1998). Subtype B is the dominant form in 
Europe and North America. Subtypes A and D are found mainly in Africa, while subtype 
C is found mainly in Asia and Africa. Subtype B is the focus of most laboratories. Few 
laboratories focus on the other subtypes (Osmanov et al., 2002). 
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Cluster Designation Marker CD4 And CD8 
CD4 (cluster of designation 4) is a glycoprotein found on the surface of immune 
cells, especially T helper cells. CD4+ T helper cells are white blood cells that are an 
essential part of the human immune system. They are called helper cells because one of 
their main roles is to organize the action of other cells in the immune system. The role 
that CD4+ T helper cells play make them the main core of the immune system and 
depletion of these cell leads to severe failure in the immune system like in HIV and 
DiGeorge syndrome. CD4+ T helper cells use T cell receptor to communicate with MHC 
class II molecules on the surface of the antigen-presenting cell. CD4 is a co-receptor that 
assists the T cell receptor in the process of communication. The intracellular domain of 
CD4 amplifies the signal generated by the T cell receptor by recruiting tyrosine kinase 
Lck enzyme. This enzyme will active other enzymes and molecular components of the 
signaling cascade inside activated T cells. 
 
CD8 (cluster of designation 8) is a glycoprotein found on the surface of immune 
cells especially cytotoxic T cells. Recognizing and eliminating cancer cells, and virus 
infected cells are the two main functions of CD8 + T cells. By recognizing any changes 
in the MCH Class I molecules, the extracellular domain of CD8 receptor will attach to 
MCH Class I molecules and if any change is recognized by this receptor the cytotoxic T 
cell will get activated and eliminate the target cell. 
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Statistics And Epidemiology 
Of the estimated 35.3 million people with HIV/AIDS worldwide 9.7 million 
people receive high active antiretroviral therapy (HAART). The number of infected 
Females is 16.8 million of the infected people and 3.4 million are less than 15 years old  
(UNAIDS, 2012). The number of new infections at 2012 is 2.3 million. Compared with 
3.1 million new infections recorded at 2001. The number of death from AIDS in 2012 is 
about 1.6 million which has been reduced if compared to 2.2 million in 2005 (UNAIDS, 
2011). In 2010, about 68% (22.9 million) of all HIV cases and 66% of all deaths (1.2 
million) were recorded in Sub-Saharan Africa. Making Sub-Saharan Africa the region 
most affected with this global epidemic. AIDS causes 10% of all deaths in children in 
Sub-Saharan Africa. The largest population of people with HIV 5.9 million is in South 
Africa. Life expectancy in countries with high HIV rate has fallen from 65 to 35 years 
like in Botswana (UNAIDS, 2011). 
 
Transmissibility Of HIV 
The three main routes of HIV transmission are sexual contact, exposure to 
infected body fluids or tissues, and vertical transmission from mother to child during 
pregnancy, delivery, or breastfeeding. Sexual contact is considered to be the most 
frequent mode of HIV transmission where heterosexual contact represents the majority of 
all transmissions worldwide. In the United States male homosexual population accounts 
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for 64% of all new cases, making homosexual contact the most common cause of HIV 
transmission in USA (Rom & Markowitz, 2007). Anal intercourse has a high risk of 
transmission (1.4-1.7 % per act) compared with vaginal intercourse 0.38% per act (Boily  
et al., 2009). The risk of transmission from oral sex is relatively low 0–0.04% per act 
(Pattman et al., 2010). The risk of female-to-male transmission in settings involving 
prostitution in low income countries has been estimated as 2.4% per act and male-to-
female transmission as 0.05% per act (Boily et al., 2009).  
 
Sexually transmitted disease with genital ulcers increases the risk of HIV 
transmission to approximately five-fold. Smaller increase in the risk of HIV transmission 
is associated with other sexually transmitted disease, and by the parenteral route which is 
between 0.63 and 2.4% per act (Rom & Markowitz, 2007).  0.3 % per act is the risk of 
contracting HIV from a needle stick from an HIV-infected person. Furthermore, mucous 
membrane exposure to infected blood has the risk of 0.09% or 1 in 1000 per act 
(Baggaley et al., 2006). 8% of all new cases of HIV in the United States are from IV drug 
abusers in 2010 (CDC, 2012). The risk of contracting HIV from infected blood is about 
93%. Because of HIV screening for the blood donor and donated blood, the risk of  HIV 
transmission from  blood transfusion is extremely low in developed countries( Baggaley 
et al.,  2006). On the other hand, only half of transfusions may be appropriately screened 
in low income countries. Because of this, up to 15% of HIV infections in these areas 
happen due to transfusion of infected blood and blood products (UNAIDS, 2011). 
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According to the CDC, tattoos, and piercings carry theoretical risk of transmitting HIV, 
yet no confirmed cases have been documented (CDC, 2012). Mosquitoes and other blood 
sucking insects cannot transmit HIV because it cannot survive the digestive systems of 
these insects (Crans, 2010).  
 
Pregnancy, delivery, and breastfeeding are the three possible routes of HIV 
transmission from mother to child. Without treatment of the infected mother, the risk of 
HIV transmission before or during delivery is about 20% and with breastfeeding the risk 
will increase to 35% (Coustsoudis et al., 2010). 90% of HIV cases in children are caused 
by vertical transmission. The high risk of vertical transmission can be reduced to about 1 
% with appropriate management and treatment. For infected mother taking antiretroviral 
during pregnancy and delivery, doing elective caesarean delivery, avoiding breastfeeding, 
and administering antiretroviral drugs to the newborn are considered adequate to reduce 
the risk of vertical transmission (Coustsoudis et al., 2010). Exposure to feces, nasal 
secretions, saliva, sputum, sweat, tears, urine, or vomit carry no risk of transmitting HIV  
unless these materials are contaminated with blood (Kripke, 2007). 
 
HIV Signs And symptoms. 
Acute infection, latency, and AIDS are the three stages of HIV infection. Acute 
infection is the first stage after incubation period. The duration of acute infection or 
primary HIV infection is several weeks. Acute HIV infection or acute seroconversion 
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syndrome symptoms are similar to the influenza or infectious mononucleosis symptoms. 
These symptoms include sore throat, fever, lymphadenopathy, headache, malaise, rash, 
and myalgia. Infected individuals can be asymptomatic (Kahn & Walker, 1998). 
Nonspecific symptoms of acute HIV make it very difficult to diagnose the acute stage. 
Yet some points in the patients’ history like unprotected sex and multiple sexual partners 
may provide a strong clue. Recognizing HIV infection during acute stage is very 
important because the patient is  highly infectious during this period (Darr et al., 2001). 
 
According to the virus activity and host immunity, the latency stage takes from 
seven  to ten years (Colledge et al., 2010) During this phase the host immunity will 
reduce the number of viral particles in the circulation, and the host will be symptom free. 
However, HIV is still active within lymph nodes leading to persisting swelling of the 
involved lymph nodes because of large amounts of virus will become trapped  in the 
follicular dendritic cells (Burton al,. 2002). 
 
AIDS 
AIDS is the final stage of HIV infection. It is defined by low CD4+ T cell counts 
(less than 200 per microliter), various opportunistic infections, cancers and other 
conditions. Opportunistic infections symptoms are the main symptoms of AIDS. Most 
opportunistic infections are caused by bacteria, viruses, fungi and parasites that are 
normally eliminated by cellular immunity, especially CD4 + T lymphocytes. Beside 
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opportunistic infections, patients with AIDS have a high risk of developing certain kinds 
of cancers like Kaposi's sarcoma, cancers of the immune system   like lymphoma, and 
cervical cancer (Holmes et al., 2003). 
 
AIDS Pathophysiology 
A massive increase in virus numbers in the peripheral blood occurs after a period 
of rapid viral replication. This increase happens immediately after virus entrance to the 
human body. During primary infection, the level of HIV may reach several million virus 
copies per milliliter of blood (Piatak et al., 1993). In the same time, CD4 counts will 
decrease and CD8 + T cells will be activated due to acute viremia. After seroconversion 
the activated CD8 + T cells will attack and kill HIV-infected cells with help of 
antibodies. Killing of HIV infected cells by CD8 + T cells shows the importance of 
CD8+ T cell in controlling virus levels and restoring the CD4+ T cell counts. Many 
patients with a good CD8+ T cell response demonstrate slower disease progression and a 
better prognosis (Pantaleo et al., 1997). Depletion of CD4 T cells is the main cause of 
AIDS. There is a difference between the mechanism of CD4 T cell depletion in the acute 
stage and chronic stage. In the acute phase, HIV causes CD4 cells depletion by cell lysis 
and killing of infected T helper cells by cytotoxic T cells (Hel et al., 2006). On the other 
hand, the generalized immune activation and gradual loss of the ability of the immune 
system to generate new T cells are the two main reasons for CD4 T lymphocytes 
depletion during the chronic phase (Zuckerman et al.,  2007). 
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Prevention 
Near 80% risk reduction of HIV transmission can be achieved if condom s are 
used regularly. The risk of HIV infection is less than 1% per year if a couple ,of which 
one is infected,  used condoms consistently ( Crosby & Bounse, 2012).Tenofovir vaginal 
gel application  immediately before intercourse shows 40%  infection risk reduction  
among African women (Celum & Baeten, 2012). On the other hand, regular use of the 
spermicide nonoxynol-9 is associated with increased risk of transmission due to its 
tendency to cause vaginal and rectal irritation (Baptista & Ramalho-Santos, 2009). By 
circumcision only, the risk of HIV transmission can reduced in heterosexual men by 
between 38% and 66% over 24 months (Siegfried et al., 2009). Based on this study and 
others, recommendations were made by  the World Health Organization and The Joint 
United Nations Programme on HIV and AIDS to consider male circumcision as a method 
of preventing female-to-male HIV transmission in 2007. Decrease in high risk behaviors 
was noticed after implementation of comprehensive sexual education at school 
(Ljubojević & Lipozenčić, 2010). Counseling and free HIV test do not change high  risk 
behaviors in those who test negative, however it does increase condom use in those who 
test positive ( Fonner et al., 2012).  
 
Pre-exposure prophylaxis (PrEP) can be defined as administration of antiretroviral 
drugs in high risk people where studies have shown it to be beneficial. Starting 
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antiretroviral treatment in  patients with HIV whose CD4 count ≥ 350cells/µL protects 
96% of their partners from HIV ( Anglemyer et al., 2011) Daily use of  Tenofovir, with 
or without Emtricitabine  decreased risk of HIV transmission in heterosexual male, young 
heterosexuals in Africa, and  heterosexual couples where one is HIV positive ( Celum &  
Baeten, 2012). Following recommended precautions within the health care facilities is 
effective in decreasing the risk of HIV transmission ("Recommendations for prevention 
of HIV transmission in health-care settings," 1987). Needle-exchange programs and 
opioid substitution therapy are two ways to decrease risk of HIV infection among 
intravenous drug abusers (MacArthur et al., 2012).  
 
Post-exposure prophylaxis (PEP) is a course of antiretrovirals administered within 
48 to 72 hours after exposure to HIV-positive blood or genital secretions. Following a 
needle-stick injury, administration of  zidovudine reduces the risk of a HIV infection 
five-fold. In contrast, the use of tenofovir, emtricitabine, and raltegravir as PEP will 
reduce the risk more than five-fold (Kuhar et al., 2013). In case of sexual assault, PEP 
treatment is recommended for four weeks to reduce the risk of HIV transmission (Young 
et al., 2007). Measures recommended to reduce the risk of HIV vertical transmission 
from mothers to children include the use of a combination of antiviral drugs during 
pregnancy and after birth, bottle feeding instead of breastfeeding, and cesarean section. 
These measures can reduce rates of transmission by 92–99 % (Coutsoudis et al.,  2010). 
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Super Active Latex Beads. 
 
 Super active latex beads are hydrophilic and contain a very high density of 
functional groups for covalent coupling of proteins to the particles. The super active layer 
is a three-dimensional layer which increases the colloid stability of the particles and 
provides a 'soft landing' for the proteins. There is less distortion of the protein structure 
than if it were physically adsorbed to a rigid surface. There are 5 types of the super active 
latex beads Carboxylate Modified beads (CML) , Chloromethyl beads, Aldehyde/Sulfate 
beads, Aldehyde/Amidine beads, and Aliphatic Amine. In this study, we used carboxylate 
modified beads. CML beads are produced by copolymerizing carboxylic acid containing 
polymers. The result is a latex polymer particle with a highly charged, relatively 
hydrophilic surface , and pka of 5-9. These characteristics will help the CML to be used 
in plasma, and in aqueous environment with pH range from 5-9 with less tendency of 
aggregation (Super Active Latex Beads,” n.d.) . 
 
Bead Method 
The main objective of the bead method is to coat inert latex spheres with CD4 or 
CD8 mouse monoclonal antibody, and use these beads to identify and manually 
enumerate by light microscopy the absolute count of CD4+ or CD8+ lymphocytes in a 
19 
 
fresh sample of mouse spleen cells. The lymphocyte population of mouse spleen is 
composed of different cell types, including CD4 T lymphocytes and CD8 T lymphocytes. 
These cells types are morphologically indistinguishable by light microscopy but can be 
differentiated by characteristic antigenic differences in their cell membranes. The main 
purpose of developing monoclonal antibodies is to identify and enumerate T and B 
lymphocytes (Foon KA and Todd RF 1986). In comparison to the relatively nonspecific 
polyclonal antibodies produced against these cellular populations, monoclonal antibodies 
can more specifically identify T cell and B-cell surface antigens. The main idea of the 
beads method is to coat inert latex spheres with CD4 or CD8 mouse monoclonal 
antibody, and use these beads to identify and manually enumerate by light microscopy 
the absolute count of CD4+ or CD8+ lymphocytes in fresh sample, of mouse spleen cells 
suspensions.  
 
Diagnosis 
Because AIDS has nonspecific symptoms,  many HIV-positive people are 
unaware that they are infected with the virus. In 2001, HIV testing was performed on less 
than 1% of the sexually active urban population in Africa. Similarly, in urban women 
health care clinic only 0.5% of pregnant women were counselled, tested or provided with 
their test results (Kumaranayake & Watts, 2001). The screening test for HIV is enzyme-
linked immunosorbent assay (ELISA).  The screening test detects antibodies to HIV. 
Patients with nonreactive results from ELISA are considered HIV-negative. A patient 
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with a reactive ELISA result is retested in duplicate . If the result of either duplicate test 
is reactive, the patient is reported as repeatedly reactive and undergoes confirmatory 
testing.  Western blot is the confirmatory test for HIV. Patients who are repeatedly 
reactive by ELISA and positive Western blot are considered HIV-positive indicating HIV 
infection. Patients with repeatedly reactive ELISA and an indeterminate Western blot 
result are considered to show either an incomplete antibody response to HIV or 
nonspecific reactions in an uninfected person. In case of indeterminate test result Western 
blot test should be repeated after one month (CDC, 2006). According to the CDC HIV 
can be classified in to three stages according to CD4 count and clinical symptoms. 
Stage 1: CD4 count ≥ 500 cells/µl and no AIDS defining conditions. 
Stage 2: CD4 count 200 to 500 cells/µl and no AIDS defining conditions. 
Stage 3: CD4 count ≤ 200 cells/µl or AIDS defining conditions(CDC, 2008). 
The ratio of CD4 to CD8 gives an idea about the impact of HIV on the Immune system. 
The normal ratio of CD4/CD8 is 2 to 1. In AIDS patients the CD4/CD8 ratio is reversed 
because of the decrease in the CD4 counts. However, with anti-retroviral treatment, this 
ratio will return to normal 2 to 1. The main use of CD4/CD8 ratio is to monitor the 
response of HIV patients to antiretroviral treatment.  CD4/CD8 ratio is also used in the 
diagnosis of HIV infection in infants under the age of 18 months. The CD4/CD8 ratio test 
is 98.3% specific and ≥ 98.7% sensitive  for identifying infant HIV-1 infection (all 
subtype C) (Zijenah et al., 2006).  
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Another test used to monitor HIV infection is viral load in patients’ serum. Viral 
load can be calculated by estimating the virus RNA in the plasma in the form of RNA 
copies per milliliter of plasma. The relationship between the viral load and CD4 + T 
lymphocytes is inverse relationship. Knowing the absolute CD 4 + T lymphocytes will 
indicate the viral load level if it is high or low. Viral load is considered a very important 
prognostic marker of disease progression and provide  valuable information about 
patients  response  for the therapeutic strategy. On the other hand , CD4 + T lymphocytes 
counts provide important  clues about when to initiate treatment with antiretroviral 
therapy ,and the time to start opportunistic infections prophylaxis (Saag et al., 1996). For 
these reasons we chose CD4 + and CD8 + T lymphocytes as a markers to stage and 
monitor HIV patients in our study. For sure using CD4 + T lymphocytes and Viral load  
will give a more holistic view about  the patients conditions , even though  our study 
where directed toward a regions with limited resources  and laboratory ability. 
 
 
Management 
Currently, there is no cure or effective HIV vaccine. The main treatment for HIV 
consists of a mixture of antiretroviral drugs HAART. The medication regime does not 
eliminate HIV, yet it slows the progression of the disease to its final stages (May & Ingle 
et al., 2011). HAART is a combination of at least three medications belonging to  two 
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different classes of antiretroviral agents. The initial regimen consists of a non-nucleoside 
reverse transcriptase inhibitor (NNRTI) plus two nucleoside analogue reverse 
transcriptase inhibitors (NRTIs)  (Colledge et al., 2010). The most common used NRTIs 
include zidovudine (AZT) or lamivudine and tenofovir (TDF). If the above regimen is not 
effective in controlling the disease, combinations of agents which include protease 
inhibitors (PI) are used (Colledge et al., 2010). WHO recommends starting antiretrovirals 
in all adolescents, adults and pregnant women with a CD4 count less than 500/µl. 
However, treatment can be started if patients have symptoms regardless of CD4 count. 
Beginning treatment when CD4 counts are less than 500/μl reduces the risk of death 
(Siegfried et al., 2010).  
 
Once treatment is begun  it should be  continued without breaking. The main goal 
of treatment is to maintain plasma HIV-RNA count below 5000 copies/mL. If treatment 
is effective, levels fall below 5000 copies/ ml after four weeks. Once 5000 copies/mL 
viral load is reached, viral load should be measured every three to four months. More 
than 5000 copies/ml viral load is considered inadequate control of HIV activity (Saag, M 
S, 1996). During the first year of treatment, HAART is effective in more than 95% of 
patients (Vogel et al., 2010). HAART helps in decreasing the risk of HIV transmission to 
sexual partners and from mother to child, progression to AIDS, and a decreased risk of 
death due to HIV (Sterne et al., 2009).  The risk of acquiring tuberculosis is reduced by 
70% with treatment. The most common side effects of protease inhibitors are 
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lipodystrophy syndrome, dyslipidemia, and diabetes mellitus (Fantry, 2003). Nucleoside 
and non-nucleoside reverse transcriptase inhibitors can cause different side effects like 
fatigue, myalgia, proximal weakness, dilated cardiomyopathy, and peripheral lipoatrophy 
(Carr & Cooper, 2000). Efavirenz should be avoided in the first trimester of pregnancy 
because of reported cases of fetal neural tube defects (Vogel et al., 2010).All this 
spectrum of sides effects make it necessary to give antiretroviral drugs for the patients 
who need them. To decide if a patient needs to be treated or not, physician must put the 
patients in the correct HIV stage. Staging HIV patients will make them avoid unnecessary 
exposure to the possible side effects of the antiretroviral therapy, and provide good 
distribution of the antiretroviral therapy in resources limited regions.  
 
In a situation where there is no access to flow cytometry it is impossible to stage 
HIV patients. Flow cytometry requires  a reliable  power supply, the cost of a flow 
cytometry  ranges from $30,000 to $150,000, and the reagents needed for determining the 
lymphocyte surface markers by this method are very costly. In addition, use of flow 
cytometry requires technical and operational expertise. Taking into consideration all 
these factors, it is clear that flow cytometry is not always available in developing world 
countries. These facts make the bead method the best alternative for the flow cytometry 
in the developing countries. The bead method will help in staging HIV patients, and 
initiating HAART. Furthermore, monitoring patients and determining if the patients are 
responding to the treatment is another important use of the bead method. 
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Chemoprophylaxis against opportunistic infections is started at different levels of CD4 
counts. For example, when CD4 count is less than 200 cell /μl chemoprophylaxis against 
Pneumocystis Jirovecii is started. This is other area where the bead method can be used to 
determine when to initiate chemoprophylaxis against opportunistic infections. Recently, 
WHO and the Global Fund to Fight AIDS have launched global campaigns against AIDS 
in Africa and other developed countries. One of the campaign targets is to distribute 
HAART to millions of patients. Without a reliable readily accessible method to count 
CD4 T cells, these major efforts will not be able to provide medications where they are 
most needed. 
 
MATERIALS AND METHODS 
 
Animals And Spleen Harvesting 
Spleens from 4 month old ICR female mice were harvested in the laboratory of  
Dr. Emily Dudly. Harvested spleens were kept in Dulbecco’s Modified Eagle’s Medium 
(DMEM) (HyClone, Fisher Scientific, Pittsburgh,Pa). Spleens were macerated between 
the frosted ends of two microscope slides. The resulting cells suspension was centrifuged 
for 5 minutes at 1500 rpm. The cells were re-suspended in 5 ml 1x PBS and the spleen 
cells suspension was ready to be analyzed by the Bead method, and flow cytometry. 
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Principles Of The Bead Method 
Three reagents are required to count CD4 or CD8 using beads method. These 
reagents are labeling reagent, blocking reagent, staining reagent (Figure 2) .The Labeling  
reagent consists of 1.4 μm carboxylate modified super-active latex Beads ( Life 
Technologies, Grand Island, NY )  coated with CD4 purified mouse  monoclonal 
antibody ( Biolagend , San Diego, CA ). The bead method depends on the ability of 
monoclonal antibody-coated latex beads to bind to the surface of T lymphocytes 
expressing CD4 or CD8. When the CD4 or CD8 coated latex spheres come in contact 
with a cell that has the CD4 or CD 8 cell surface antigen, the two bind, forming a cell-
latex beads rosette that is readily recognized by light microscopy. The blocking Reagent 
contains 0.5 μm in diameter carboxylate modified super active latex beads (Life 
Technologies, Grand Island, NY). The beads in this reagent are coated with CD 14 
purified mouse monoclonal antibody (Biolagend, San Diego, CA) to minimize the 
reactivity of monocytes against CD4 coated latex spheres and reduce nonspecific binding 
with CD4 coated beads. The staining reagent consists of 2% acetic acid in distilled water 
and 0.025% crystal violet stain. The function of staining reagent is to lyse red blood cells, 
and stain lymphocytes. 
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Figure 2. Bead Method Reagents. B blocking reagent, L labeling reagent, and S 
staining reagent.  
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Reagents Preparation 
For the blocking and labeling reagent passive adsorption method was used to coat 
the beads. The passive adsorption method is a simple method for the attachment of 
antibodies by physical adsorption to carboxylate modified super active latex beads. 
The materials needed for this method are carboxylate modified super active latex beads, 
2- n-morpholino-ethanesulfonic acid ( MES ) (Fisher Scientific, Pittsburgh, PA) buffer, 
0.025 M, pH 6, wash buffer  phosphate-buffered saline (PBS), 0.1 M, pH 7.2 , and 
storage Buffer   phosphate-buffered saline (PBS), 0.1 M, pH 7.2,0.1% glycine; 0.1% 
NaN3 sodium azide . We chose MES buffer because its pH value is close to the 
isoelectric point of the antibodies used in this study, maximizing  the protein density on 
the particle surface. Buffer systems contain multivalent anions (phosphate or borate) are 
not used in coating the latex microspheres because these ion species will compromise the 
colloidal stability of the latex beads. 
 
MES Buffer Preparation 
To prepare 10 ml of MES buffer with 0.025 M, and pH 6 we weighted 48,8 mg of 
MES and added  it to 5 ml of Double distilled water.   Since the starting pH would be 
below 4.0, a pH electrode was used to titrate to pH 6.0 with 1 N NaOH. Once the solution 
was adjusted to the correct pH, it was transferred to a graduated cylinder or volumetric 
flask and diluted to a final volume of 10 mL. 
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Storage Buffer Preparation 
Glycine was used in the storage buffer to fill any reactive sites on the microsphere 
surface which had not been covered by the protein, and to reduce non-specific binding. 
Bovine serum albumin (BSA) might be used for the same purpose. The NaN3 was 
present as a biocide. If the latex is kept sterile, NaN3, which is not compatible with cell 
or tissue culture, can be omitted. Storage buffer was prepared by mixing 100 mg glycine, 
100 mg sodium azide, and brought to a volume of 10 ml with PBS. 
 
Determining Antibody And Latex Quantities 
By using the following equation the optimal amount antibody needed for the 
beads coating was calculated.  
Weight of the antibody=
Weight the antibody for the total particle weight
Diameter of the partical in μm
. 
In this study 100 mg of 1.4 μm latex beads were coated with 2 mg of CD4 antibody. 
According to the equation, weight of the antibody =
2 mg
1.4 μm
  = 1.4 mg of CD4 antibody is 
needed to coat 100 mg of the beads. The same amount of CD8 antibodies was used to 
cote beads with CD8 antibody. Similarly, we coated 100 mg of 0.5 μm latex beads with 1 
mg of CD14 blocking  antibody , and according to the equation  =
1 mg
0.5 μm
  = 2 mg of CD 
14 antibody is needed to coat 100 mg of the beads. 
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Latex Beads Coating 
To coat latex beads with CD4, CD8, or CD14 we pipetted 2.5 ml (40 mg/ml) latex 
microspheres and diluted with 10 ml MES buffer. Then we centrifuged the mixture to 
sediment the particles with 3,000g for 20 minutes. We removed the supernatant and re-
suspend the pellet in 10 ml MES buffer. We centrifuged it again and removed the 
supernatant from the particles. These washing steps were done to prepare the beads for 
coating with CD4, CD8, or CD 14 monoclonal antibodies. After that, we re-suspend 
pellet in 5 ml MES buffer to make.The latex suspension approximately 2 % solids (20 
mg/ml). We added 5 ml MES buffer to prepare CD4 or CD8 coated beads (labeling 
beads). For CD 14 coated beads (blocking beads), the pellet was re-suspended in 10 ml 
MES Buffer to get 1% solids percentage (10 mg/ml). We added the calculated amount of 
the antibody. The calculated amount of the antibody would ensure the best coating of the 
particles with the least possibility of aggregation. Latex/protein mixture was incubated 
with gentle mixing at room temperature overnight.  
 
In the next day, we centrifuged the latex/protein mixture to separate the protein-
labeled latex particles from unbound protein. In the next step, we Re-suspend the pellet in 
10 ml PBS. We washed the protein-labeled beads three times by centrifugation and 
suspension in 10 ml PBS. In the last step , we re-suspended the final latex of CD14 in 10 
ml Storage Buffer giving a final percentage of 1% solids, and CD4 or CD8 in 5 ml 
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storage buffer  giving final percentage of 2% solids. We stored the reagents at 4°C, and 
we did not freeze them. 
 
Measuring CD4 And CD8 Using Beads Method 
To count the CD4 or CD8 T cells by using bead method we labeled two 12 x 75  
mm tube  as L+B and S (figure 3 A). We Put 100 µl of reagent S in to the test tube  
labeled S (figure 3 A). We placed 100 µl of spleen cells suspension at the bottom of  
the test tube  labeled   B+L (figure 3 B). We Mixed reagent B before Adding 10 µl of  
reagent B to the Spleen cells suspension in the L+B  Tube (figure 3 C). Then we Held the  
test tube vertically, and mixed gently by hand for 2 minutes immediately after adding  
reagent B (figure 3 C). In the same way, we Mixed reagent L, and added 10 µl of reagent   
L to B+L test tube (figure 3 D). We Held the test tube vertically, and mixed gently by  
hand for two minutes immediately after adding reagent L. after two minutes, we added 10  
µl of the cell suspension latex spheres mixture from the B+L test tube to the S test tube  
(figure 3D). Droplets around the top of any test tube will result in non-lysis of red blood  
cells and  erroneous CD4+ or CD8+ lymphocyte counts. To lyse the red blood cells in the  
C test tube, we held the test tube vertically, and mixed gently for 10 to 15 seconds  
(figure 3 E). In the next step, we loaded both chambers of the 0.1 mm deep (or one  
chamber of the 0.2 mm deep) Hemacytometer with the sample from step 9 (figure 3 F).  
We placed the Hemacytometer in a moisture chamber and allow the cells to settle for 2 to  
3 minutes. Under the light microscope, we counted the cells that had three or more large  
latex spheres attached to them as CD4 + T lymphocytes (figure 4 A,B) or CD8 + T  
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lymphocytes (figure 4 C, D). We used the following equation to calculate the absolute  
count of CD4 or CD8 + T lymphocyte. 
. 
Absolute CD4 or CD8 + T lymphocytes/μL = 
                 
 
𝐶𝐷4 𝑜𝑟 𝐶𝐷8 +𝑇 𝑙𝑦𝑚𝑝ℎ𝑜𝑐𝑦𝑡𝑒 𝑐𝑜𝑢𝑛𝑡 𝑥 𝐶ℎ𝑎𝑚𝑏𝑒𝑟 𝑑𝑒𝑝𝑡ℎ 𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑖𝑜𝑛 𝑥 𝑆𝑎𝑚𝑝𝑙𝑒 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑖𝑜𝑛 
Surface area (mm2) 
   
 
where: 
 
Surface Area = 18 mm
2
 for two sides of 0.1 mm deep chamber 
 
Chamber Depth Correction = 
1
chember depth
 =  
1
0.1
 = 10 for 0.1 mm deep chamber. 
 
Correction For Sample Dilution: 
Primary dilution: 
100 μL whole sample 
+ 10 μl Reagent L 
+ 10 μL Reagent B = 100/20 
Secondary dilution: 
10 μL of 100/120 primary dilution 
in 100 μL Reagent S = 
 
10μl x (
100
120)
110 μl
=
1
13.2
 
 
Therefore the Correction for Sample Dilution =  
1÷ 
1
13.2
 = 13.2 
 
For example if the CD4 count in 0.1 mm chamber was 60. So the CD4 count in the 
sample can be calculated by applying the formula. 
 
60 𝑥 𝐶ℎ𝑎𝑚𝑏𝑒𝑟 𝑑𝑒𝑝𝑡ℎ 𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑖𝑜𝑛 (10) 𝑥 𝑆𝑎𝑚𝑝𝑙𝑒 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑖𝑜𝑛 (13.2)
Surface area (18 mm2 )
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60x 7.3 = 438 CD 4 + T lymphocytes /μl. 
From the equation a conversation matrix was created to know the concentration of CD 4  
or CD8 + T lymphocyte in the sample (Table 1). Lymphocytes with no attached beads  
(figure 5 A,C) , one (figure 5 B,C) , or  two bead attachments will not be counted . 
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Figure 3. Bead Method Protocol. (A-F). Figure shows different steps of the bead 
method. 
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Figure 4.  Bead Method Results Three Or More Beads Attachment. Microscopic 
images at 40X magnification demonstrate three beads and more attaching  to CD4  and 
CD8  T lymphocytes (A,and B CD 4. C, and D CD8 ).  
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Figure 5. Bead Method Results One Or No Beads Attachment. Microscopic images at 
40X magnification demonstrate no beads attached (A,C) and one bead attached  (B, and 
C). 
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Table 1. CD4 And CD8 T lymphocytes Count Conversation Matrix. 
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Flow Cytometry CD4 And CD8 Counting 
Flow cytometry uses laser and fluidic principles for cell sorting, counting, and  
biomarker detection. By using fluidic principles, the flow cytometry aligns the cells so  
they pass in single file through the laser beam for analysis. In our study, flow cytometry  
was used to count the absolute number of CD4 T lymphocytes and CD8 T lymphocytes  
after marking them with fluorescent conjugated antibodies. Control antibody were used in  
every experiment. For CD4 T lymphocytes counts we used FITC anti-mouse CD4 
 Antibody ( Biolegend San Diego, CA, ) , and FITC Rat IgG2a, κ Isotype Ctrl Antibody  
as control ( Biolegend San Diego, CA,). For CD8 T lymphocytes we used PE/Cy5 anti- 
mouse CD8a Antibody (Biolegend, San Diego, CA ), and PE/Cy5 Rat IgG2a, κ Isotype 
 Ctrl Antibody as control ( Biolagend, San Diego, CA).  
 
To count CD4 and CD8 + T lymphocytes we washed cell suspension 3 times 
with 1% (bovine serum albumin) BSA, and centrifugation speed of  1200 rpm for 5 
minutes. After washing, we blocked the sample with 3% BSA and 30 minutes incubation.  
After the incubation, we washed the sample 3 times with 1% BSA, and centrifugation  
speed of 1200 rpm for 5 minutes. Conjugation with fluorochrome conjugated primary  
CD4 or CD8 antibody and there controls was the next step after washing. The amount of  
the antibody that was 5 μg antibody / ml with 100 μl of 3% BSA for each sample. We  
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Incubated the sample with fluorochrome conjugated   antibody for 45 minutes at 4°C in  
the dark. Then, we washed the sample with 1% BSA and centrifugation speed of 1200  
rpm for 5 minutes 3 times. After the last step of washing, we fixed the sample by   re- 
suspension in cold PBS, 10% fetal calf serum , and 1% sodium azide at 4°C until analysis  
within 24 hours. FCS Express program was used to analysis the results form flow  
cytometry (figure 6-7). 
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Figure 6. Flow Cytometry Results Of Sample Analysis Using CD4 Monoclonal 
Antibody(A-F). The figure shows flow cytometry analysis of ICR female mouse spleen 
cells suspenstion using CD4 monoclonal antibody. The  machine was adjusted to stop 
after detecting 20,000 event. Knowing the volume at which 20,000 was detected we 
calculated how many CD4 per sample = 20,000/ volume at which 20,000 was detected. 
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Figure 7. Flow Cytometry Results Of Sample Analysis Using CD8 Monoclonal 
Antibody(A-F). The figure shows flow cytometry analysis of ICR female mouse spleen 
cells suspension using CD8 monoclonal antibody. The  machine was adjusted to stop 
after detecting 20,000 event. Knowing the volume at which 20,000 was detected we 
calculated how many CD8 per sample = 20,000/ volume at which 20,000 was detected. 
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RESULTS 
The absolute number of CD4+ T lymphocytes and CD8+ T lymphocytes was 
determined using both flow cytometry and the bead method  in cells from six female ICR 
mouse four month of age. The total number of lymphocytes in ICR female mouse spleens 
was ~10 million in all six samples. The ratio of total CD4 T lymphocytes to the total 
lymphocytes counts was ~ 0.8 and ratio of  total CD8 T lymphocytes counts to the total 
number lymphocytes counts was ~ 0.4 (Table 3-4). The results show that the number of 
CD4 + T lymphocytes is more than the number CD8 + T lymphocytes. The numbers of 
CD4 + T lymphocytes were around 400 Cells /μl, and the number of CD8 + T 
lymphocytes was around 200. The ratio of CD4 to CD8 was 2:1 (Table 2) (figure 8). The 
results were analyzed by using Sigma Plot. Paired t-test shows that the correlation 
between beads and flow cytometry is greater than would be expected by chance and this 
correlation is a statistically significant (P = <0.001). One Way Analysis of Variance 
demonstrate that the differences in the mean between beads method and flow cytometry  
is greater than would be expected by chance; there is a statistically significant difference 
(P =  <0.001). Since the p value is less than 0.005 the null hypothesis can be rejected, and 
the bead method can give enough accurate estimation of the CD4 and CD8 T 
lymphocytes counts in ICR mouse spleen cells suspension. These results of this study 
provide the basis for using the bead method in situation where flow cytometry is not 
available. 
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Mouse Flow cytometry Bead Method 
  CD4 CD8 CD4 CD8 
ICR F 1 419/µl 199/µl 423/µl 204/µl 
ICR F 2 427/µl 215/µl 431/µl 219/µl 
ICR F 3 404/µl 221/µl 409/µl 226/µl 
ICR F 4 439/µl 237/µl 445/µl 241/µ 
ICR F 5 421/µl 209/µl 423/µl 212/µl 
ICR F 6 441/µl 229/µl 445/µl 226/µl 
 
Table 2. Result Of CD4 And CD8 T Cells Counts Using Flow Cytometry And Bead 
Method. The table shows  CD4 and CD8 T lymphocytes counts in 6 Female ICR mouse 
by using flow cytometry and Bead  Method. The results of both methods are not identical 
for the same sample; however, the results from the beads method are not far from flow 
cytometry results. For all the samples Bead Method estamition was higher than the flow 
cytometry.( Mean of  the flow cytometry CD4=425, CD8=218 , Mean of the Bead 
Method CD 4=429 , CD8 = 221) 
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Mouse Flow cytometry Bead Method 
  CD4/Sample CD8/Sample CD4/Sample CD8/Sample 
ICR F 1 838000 398000 846000 408000 
ICR F 2 854000 430000 862000 438000 
ICR F 3 808000 442000 818000 452000 
ICR F 4 878000 474000 890000 482000 
ICR F 5 842000 418000 846000 424000 
ICR F 6 882000 458000 890000 452000 
 
 
Table 3. Total CD4 And CD8 T Lymphocytes Counts. The table shows the total CD4 
T cells and CD8 T cells counts per sample. This table was created to calculate the ratio of 
total CD4 T cells and CD8 T cells to the total number of lymphocytes. 
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Mouse Flow cytometry Beads Method 
  CD4/ Total 
lymphocytes 
CD8/ Total 
lymphocytes 
CD4/ Total 
lymphocytes 
CD8/ Total 
lymphocytes 
ICR F 1 0.83 0.4 0.84 0.4 
ICR F 2 0.85  0.43 0.86 0.43 
ICR F 3 0.80 0.44 0.81 0.45 
ICR F 4 0.87 0.47 0.89 0.48 
ICR F 5 0.84 0.41 0.84 0.42 
ICR F 6 0.88 0.45 0.89 0.45 
 
Table 4. CD4 And CD8 T Lymphocytes Ratio To Total Lymphocytes Count. The 
table demonstriates the ratio of ratio of total CD4 T cells and CD8 T cells to the total 
number of lymphocytes. This ratio shows no large difference between the two methods 
and  supports the idea of using the beads method in staging, and monitoring HIV infected 
patients. 
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Figure 8. Bar Chart For Flow Cytometry And Bead Method Results. Bar chart shows 
the results of flow cytometry and bead method. The results of CD4 T lymphocytes counts 
are around 400 Cell/μl in both methods. In the same way, the results of CD8 T 
lymphocytes counts are around 200 cell/μl in both beads method and flow cytometry. 
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DISCUSSION 
The main goal of this study was to compare the results of counting  the absolute 
number of CD4 + T lymphocytes and CD8 + T lymphocytes  in mouse spleen cell 
suspension   using flow cytometry (gold standard method ), with the bead  method. This 
was done in anticipation of using the bead method in staging and monitoring treatment 
response in HIV infected patients. The bead method depends on the ability of monoclonal 
antibody-coated latex beads to bind to the surface of T lymphocytes expressing CD4 or 
CD8. When the CD4 or CD8 coated latex spheres come in contact with a cell that has the 
CD4 or CD8 cell surface antigen, the two bind forming a cell-latex beads rosette that is 
readily recognized by light microscopy. 
 
The bead method was not time consuming in comparison to the flow cytometry 
method. The bead method took about two hours to do all 6 samples while the flow 
cytometry method took about 4 hours. The bead method did not require a lot of 
laboratory experience. In the other hand, the flow cytometry method required more 
laboratory training and experience than the bead method. The cost of the bead method 
reagents is about $1,000, in contrast the flow cytometry cost ranges from $30,000 to 
$150,000, and the reagents needed for determining lymphocytes surface markers by this 
method are very costly. 
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The bead method slightly over estimates CD 4 and CD8 + T lymphocytes.  In 
clinical situation this slight over estimation can be acceptable because the clinical 
decision whether to treat patients or not depends on CD 4 and CD8 + T lymphocytes 
counts, and the clinical condition of the patients. Using the bead method with blood 
samples from HIV patients carries the risk of HIV infection. Yet, the risk of HIV 
infection in laboratory workers dealing with blood samples from HIV patients is 
approximately 0.3% (Kuhar et al., 2013). 
 
 In our study we did not use peripheral mice blood; instead we used mice spleen 
cell suspension. The relationship between splenic CD4 and CD8 + T lymphocytes and the 
peripheral blood CD4 and CD8 + T lymphocytes is different according the strain, sex, 
and age of the mice. In BALB/C mice the percentage of CD4 and CD8 + T lymphocytes 
in peripheral blood and in the spleen was the same in early age. However, in old age mice 
the percentage of CD4 and CD8 + T lymphocytes  decline in the peripheral blood and 
stay the same in the spleen (Pinchuk & Filipov, 2008). The use of spleen cell suspension 
does not exactly simulate the clinical situation at which the bead method intended to be 
used, however the results continuity were very promising and satisfactory to make us 
advance to the next step in this research. The next step in our study is to compare staging 
of HIV infected patients using bead method, and flow cytometry. 
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 In general, reducing the exposures to body fluids and blood is the most important 
strategy for preventing occupationally acquired HIV infection. To reduce the risk of 
contracting HIV infection while working with the bead method, we suggest adding a 
fixation step with PBS, fetal calf serum, and sodium azide. In addition, lab workers 
should deal carefully with needles and sharp objects, and use gloves when handling 
materials containing HIV. Gloves should be changed after any contact with a potentially 
contaminated surface or material. Hand washing is other way to reduce the risk of 
infection with HIV. During working with the bead method lab workers should avoid hand 
contact with mouth, eyes, ears, and nose. This requirement can be made easier by 
wearing goggles or a face shield. Decontamination of work surfaces after finishing 
working with the bead method can also help with reducing the risk of contracting HIV 
infection (Weiss et al., 2014).  
 
Flow cytometry uses laser and fluidics principles for cell sorting, counting, and 
biomarker detection. By using fluidics principles, the flow cytometry aligns the cells so 
they pass in single file through the laser beam for analysis. In this study, flow cytometry 
was used to count the absolute number of CD4 T lymphocytes and CD8 T lymphocytes 
after marking them with fluorescent conjugated antibodies. The results from the flow 
cytometry and the beads method demonstrated that the beads method will give estimation 
of the absolute CD4 and CD8 + T lymphocytes accurate enough to substitute the flow 
cytometry in case of staging, and monitoring treatment response in HIV infected patients.  
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In comparison to polyclonal antibodies, monoclonal antibodies can specifically 
identify T cell and B-cell surface antigens.  Moreover , monoclonal antibodies allow not 
only for  lymphocyte measurements but in conjunction with other cell markers like TdT 
(Terminal deoxynucleotidyl transferase) they  help in  identification of distinct stages of 
T-cell and B-cell differentiation. TdT is an enzyme that plays important role in B and T 
lymphocytes Maturation. TdT randomly adds nucleotide to the DNA of Maturating T or 
B lymphocytes in order to help them to generate Immunoglobulin surface receptors 
capable of recognizing different pathogens. The addition of the nucleotides does not 
correspond to any DNA germline sequence (Pharm, 2009).  
 
Leukemia is tumor of the white blood cells. Failure of cell maturation is the main 
cause of acute leukemia.  The immature cells Proliferate and accumulate in the bone 
marrow. The high rate of leukemic cells proliferation will take up the space and nutrient 
at the expense of the normal haematopoietic cells. When the bone marrow runs out space 
the malignant cells will spill into the blood.  Bone marrow failure clinical features are the 
clinical features of leukemia.   Since the bone marrow is responsible for production of red 
blood cells, maturation of white blood cells, and platelet synthesis, the three main clinical 
features of bone marrow failure are anemia, infection, and bleeding (Colledge, 2010). In 
case of acute lymphoblastic leukemia, the expression of TdT on the cells surface 
increases (Janossy et al., 1979). Future studies can be done about the concept of over 
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expression of TdT  in acute lymphoblastic leukemia to assess if the bead method will 
help in diagnosis and staging of this kind of leukemia.  
 
Another place where the bead method can be used is detection of CD5 and CD19 
expressed on the same white blood cells which may help in diagnosis and staging of 
chronic lymphocytic leukemia, and primary IgA nephropathy. CD5 is a cluster 
designation found on the surface of IgM-secreting B cells (B-1 cells), and also on T cells. 
Due to lack of TdT enzyme B-1 cells have limited diversity of their B-cell receptor. The 
main function of CD5 is to mitigate activating signals from the B cell receptor.  This 
mechanism B-1 cells activation will make them activated only by very strong stimuli like 
bacterial proteins (Pharm, 2009). The B-cell co-receptor is a complex of three proteins 
CD19, CD81, and CD21. The function of CD 19  is signaling chain of the receptor.CD21 
recognizes the iC3b and C3d break down products of C3b fragments (one of the 
complement factors).CD81 function is not clearly understood, however in case of 
hepatitis C virus infection CD81 acts as receptor for the virus (Pharm, 2009). 
 
Chronic lymphocytic leukemia is the most common type of leukemia. Thirty 
percent of leukemia patients having chronic lymphocytic leukemia. Sixtys to seventy 
years is the median age group for lymphoma with 2:1 male: female ratio. B lymphocytes 
in chronic lymphocytic leukemia fail to respond probably to antigens and transform in to 
plasma cells. The abnormal B lymphocytes will accumulate in the bone marrow leading 
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to bone marrow failure (Colledge, 2010). Chronic lymphocytic leukemia is latent 
malignancy, and near 70% of the cases are diagnosed incidentally on a routine blood 
checkup. Clinical symptoms of chronic lymphocytic leukemia appear in the advanced 
stage of the disease. Anemia, recurrent infections, and weight loss are the main clinical 
features of chronic lymphocytic leukemia (Colledge, 2010). Many of the malignant B 
cells in chronic lymphocytic leukemia over express CD5, and CD19. These two CD 
markers can be used in monitoring disease status during therapy (Cabezudo et al., 1997). 
In this situation, the bead method can be used to assess the effectiveness of the 
therapeutic strategies instead of flow cytometry. 
 
Other condition where the beads method can be used instead of flow cytometry is 
primary IgA nephropathy. Patients with primary IgA nephropathy will have polymeric 
IgA-dominant Ig deposition in the mesangium of kidney (Yuling et al., 2008). The main 
clinical features of primary IgA nephropathy are hematuria, headache, and fatigue. Most 
of the patients with IgA nephropathy will progress to renal failure without treatment. One 
of the pathological markers of IgA nephropathy is the present of CD5 CD19 + B Cells in 
the peripheral blood, and peritoneal fluid. The level of CD5 CD19 + B Cells decreases 
with treatment ,and  This change in the level of CD5 CD19 + B Cells can be used to 
monitor the response of IgA nephropathy patients to the treatment (Yuling et al., 2008). 
Using the bead method to measure the level of CD5 CD19 + B cells is another clinical 
setting where the bead method can be used instead of flow cytometry. 
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